The CEO of Pfizer Incorporated said Tuesday, Sept. 26, that nearly 250,000 cycles of pharmaceutical manufacturer Paxlovid’s oral antiviral treatment COVID-19 are being administered weekly as cases rise in the United States.
Speaking at Cantor Fitzgerald’s Annual Health Care Conference, CEO Albert Bourla said the company doesn’t yet know when Paxlovid, recently distributed through the government, will get approval for sale in the U. S. advertising market.
Paxlovid, which is taken for five days after the onset of symptoms, is used to treat adults at increased risk of hospitalization and death from COVID-19.
Bourla, however, said Pfizer is in a position to get its COVID-19 vaccines with a smooth transition to the advertising market.
“Enough products have been made and we continue to make them,” Bourla said. “We are confident that the market will be highly supplied. “
In the first week after the latest COVID-19 vaccines became available in the U. S. In the U. S. , its implementation experienced setbacks as other people reported that pharmacies turned them down to get vaccinated.
Pfizer has sold about 24 million Paxlovid cures to the U. S. government. The U. S. Department of Health and Human Services has distributed about 15 million so far, according to information from the U. S. Department of Health and Human Services. U. S.
According to IQVIA data published by study analysts, the oral antiviral treatment Paxlovid against COVID-19 reached approximately 217,000 prescriptions in the U. S. UU. la week of September 1, but has declined since then. – Rappler. com